Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections https://www.medrxiv.org/content/10.1101/2021.08.24.21262415v...
Prior COVID-19 protects against reinfection, even in the absence of detectable antibodies https://www.journalofinfection.com/article/S0163-4453(21)002...
SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) https://pubmed.ncbi.nlm.nih.gov/33844963/
Risk of Reinfection After Seroconversion to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Population-based Propensity-score Matched Cohort Study https://academic.oup.com/cid/advance-article/doi/10.1093/cid...
Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting https://academic.oup.com/cid/advance-article/doi/10.1093/cid...
Assessment of SARS-CoV-2 Reinfection 1 Year After Primary Infection in a Population in Lombardy, Italy https://jamanetwork.com/journals/jamainternalmedicine/fullar...
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy https://www.sciencedirect.com/science/article/pii/S258953702...
Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection https://jamanetwork.com/journals/jamainternalmedicine/fullar...
Quantifying the risk of SARS-CoV-2 reinfection over time https://pubmed.ncbi.nlm.nih.gov/34043841/
Longitudinal observation of antibody responses for 14 months after SARS-CoV-2 infection https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325385/
Persistence of neutralizing antibodies a year after SARS-CoV-2 infection https://www.medrxiv.org/content/10.1101/2021.07.13.21260426v...
Antibody Responses 8 Months after Asymptomatic or Mild SARS-CoV-2 Infection https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920668/
Necessity of COVID-19 vaccination in previously infected individuals https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v...
Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections https://www.medrxiv.org/content/10.1101/2021.08.24.21262415v...
Prior COVID-19 protects against reinfection, even in the absence of detectable antibodies https://www.journalofinfection.com/article/S0163-4453(21)002...
SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) https://pubmed.ncbi.nlm.nih.gov/33844963/
Risk of Reinfection After Seroconversion to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Population-based Propensity-score Matched Cohort Study https://academic.oup.com/cid/advance-article/doi/10.1093/cid...
Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting https://academic.oup.com/cid/advance-article/doi/10.1093/cid...
Assessment of SARS-CoV-2 Reinfection 1 Year After Primary Infection in a Population in Lombardy, Italy https://jamanetwork.com/journals/jamainternalmedicine/fullar...
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy https://www.sciencedirect.com/science/article/pii/S258953702...
Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection https://jamanetwork.com/journals/jamainternalmedicine/fullar...
Quantifying the risk of SARS-CoV-2 reinfection over time https://pubmed.ncbi.nlm.nih.gov/34043841/
Longitudinal observation of antibody responses for 14 months after SARS-CoV-2 infection https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325385/
Persistence of neutralizing antibodies a year after SARS-CoV-2 infection https://www.medrxiv.org/content/10.1101/2021.07.13.21260426v...
Antibody Responses 8 Months after Asymptomatic or Mild SARS-CoV-2 Infection https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920668/
Necessity of COVID-19 vaccination in previously infected individuals https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v...